Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Chicago
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age ≥ 18
Confirmed diagnosis of multiple myeloma
Newly-diagnosed multiple myeloma, or relapsed/refractory multiple myeloma with receipt of 1-3 previous lines of therapy and with a 2-week washout from prior therapy
Receiving carfilzomib as either standard-of-care therapy or as part of a clinical trial
You may not be if
Previous receipt of anthracycline chemotherapy
Previous receipt of carfilzomib
Four or more previous lines of therapy
Active pregnancy at the time of enrollment
Clareo Health | Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive Carfilzomib
